Background: Lactate protects mice against the ischaemic damage resulting from transient middle cerebral artery occlusion (MCAO) when administered intracerebroventricularly at reperfusion, yielding smaller lesion sizes and a better neurological outcome 48 h after ischaemia. We have now tested whether the beneficial effect of lactate is long-lasting and if lactate can be administered intravenously. Methods: Male ICR-CD1 mice were subjected to 15-min suture MCAO under xylazine + ketamine anaesthesia. Na l-lactate (2 µl of 100 mmol/l) or vehicle was administered intracerebroventricularly at reperfusion. The neurological deficit was evaluated using a composite deficit score based on the neurological score, the rotarod test and the beam walking test. Mice were sacrificed at 14 days. In a second set of experiments, Na l-lactate (1 µmol/g body weight) was administered intravenously into the tail vein at reperfusion. The neurological deficit and the lesion volume were measured at 48 h. Results: Intracerebroventricularly injected lactate induced sustained neuroprotection shown by smaller neurological deficits at 7 days (median = 0, min = 0, max = 3, n = 7 vs. median = 2, min = 1, max = 4.5, n = 5, p < 0.05) and 14 days after ischaemia (median = 0, min = 0, max = 3, n = 7 vs. median = 3, min = 0.5, max = 3, n = 7, p = 0.05). Reduced tissue damage was demonstrated by attenuated hemispheric atrophy at 14 days (1.3 ± 4.0 mm3, n = 7 vs. 12.1 ± 3.8 mm3, n = 5, p < 0.05) in lactate-treated animals. Systemic intravenous lactate administration was also neuroprotective and attenuated the deficit (median = 1, min = 0, max = 2.5, n = 12) compared to vehicle treatment (median = 1.5, min = 1, max = 8, n = 12, p < 0.05) as well as the lesion volume at 48 h (13.7 ± 12.2 mm3, n = 12 vs. 29.6 ± 25.4 mm3, n = 12, p < 0.05). Conclusions: The beneficial effect of lactate is long-lasting: lactate protects the mouse brain against ischaemic damage when supplied intracerebroventricularly during reperfusion with behavioural and histological benefits persisting 2 weeks after ischaemia. Importantly, lactate also protects after systemic intravenous administration, a more suitable route of administration in a clinical emergency setting. These findings provide further steps to bring this physiological, commonly available and inexpensive neuroprotectant closer to clinical translation for stroke.

Keywords:
Lactate, Cerebral ischaemia, Stroke, Neuroprotection, Translational research, Middle cerebral artery occlusion
1.
Pellerin L, Magistretti PJ: Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization. Proc Natl Acad Sci USA 1994;91:10625–10629.
2.
Suzuki A, Stern SA, Bozdagi O, Huntley GW, Walker RH, Magistretti PJ, Alberini CM: Astrocyte-neuron lactate transport is required for long-term memory formation. Cell 2011;144:810–823.
3.
Schurr A, Payne RS, Miller JJ, Rigor BM: Brain lactate is an obligatory aerobic energy substrate for functional recovery after hypoxia: further in vitro validation. J Neurochem 1997;69:423–426.
4.
Schurr A, Payne RS, Miller JJ, Rigor BM: Brain lactate, not glucose, fuels the recovery of synaptic function from hypoxia upon reoxygenation: an in vitro study. Brain Res 1997;744:105–111.
5.
Ros J, Pecinska N, Alessandri B, Landolt H, Fillenz M: Lactate reduces glutamate-induced neurotoxicity in rat cortex. J Neurosci Res 2001;66:790–794.
6.
Berthet C, Lei H, Thevenet J, Gruetter R, Magistretti PJ, Hirt L: Neuroprotective role of lactate after cerebral ischemia. J Cereb Blood Flow Metab 2009;29:1780–1789.
7.
Benakis C, Bonny C, Hirt L: JNK inhibition and inflammation after cerebral ischemia. Brain Behav Immun 2010;24:800–811.
8.
Granziera C, Thevenet J, Price M, Wiegler K, Magistretti PJ, Badaut J, Hirt L: Thrombin-induced ischemic tolerance is prevented by inhibiting c-Jun N-terminal kinase. Brain Res 2007;1148:217–225.
9.
Michel-Monigadon D, Bonny C, Hirt L: c-Jun N-terminal kinase pathway inhibition in intracerebral hemorrhage. Cerebrovasc Dis 2010;29:564–570.
10.
Carter RJ, Morton J, Dunnett SB: Motor coordination and balance in rodents. Curr Protoc Neurosci 2001;8:8.12.
11.
Allaman I, Pellerin L, Magistretti PJ: Glucocorticoids modulate neurotransmitter-induced glycogen metabolism in cultured cortical astrocytes. J Neurochem 2004;88:900–908.
12.
Rosenberg JC, Rush BF: An enzymatic-spectrophotometric determination of pyruvic and lactic acid in blood. Methodologic aspects. Clin Chem 1966;12:299–307.
13.
Smith D, Pernet A, Hallett WA, Bingham E, Marsden PK, Amiel SA: Lactate: A preferred fuel for human brain metabolism in vivo. J Cereb Blood Flow Metab 2003;23:658–664.
14.
Qu H, Haberg A, Haraldseth O, Unsgard G, Sonnewald U: (13)C MR spectroscopy study of lactate as substrate for rat brain. Dev Neurosci 2000;22:429–436.
15.
Ichai C, Armando G, Orban JC, Berthier F, Rami L, Samat-Long C, Grimaud D, Leverve X: Sodium lactate versus mannitol in the treatment of intracranial hypertensive episodes in severe traumatic brain-injured patients. Intensive Care Med 2009;35:471–479.
16.
The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581–1587.
17.
Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von KR, Wahlgren N, Toni D: Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317–1329.
18.
Higuchi T, Fernandez EJ, Maudsley AA, Shimizu H, Weiner MW, Weinstein PR: Mapping of lactate and N-acetyl-l-aspartate predicts infarction during acute focal ischemia: in vivo 1 h magnetic resonance spectroscopy in rats. Neurosurgery 1996;38:121–129;discussion 129–130.
19.
Alf MF, Lei H, Berthet C, Hirt L, Gruetter R, Mlynarik V: High-resolution spatial mapping of changes in the neurochemical profile after focal ischemia in mice. NMR Biomed 2012;25:247–254.
20.
Lei H, Berthet C, Hirt L, Gruetter R: Evolution of the neurochemical profile after transient focal cerebral ischemia in the mouse brain. J Cereb Blood Flow Metab 2009;29:811–819.
21.
Berthet C, Lei H, Gruetter R, Hirt L: Early predictive biomarkers for lesion after transient cerebral ischemia. Stroke 2011;42:799–805.
22.
Lee Y, Morrison BM, Li Y, Lengacher S, Farah MH, Hoffman PN, Liu Y, Tsingalia A, Jin L, Zhang PW, Pellerin L, Magistretti PJ, Rothstein JD: Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature 2012;487:443–448.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.